Term
| AntiAnxiety Classifications |
|
Definition
| Benzodiazepine, Propanediol Compounds, Diphenylmethanes, Other (Buspar, Inderal, Anafranil) |
|
|
Term
|
Definition
| high abuse potential, drowsiness, ataxia, lethargy, H/A, vertigo, rash, rage/hostility (paradoxical reaction) |
|
|
Term
|
Definition
| Librium, Valium, Xanax, Tranzene, Ativan, Halcion, Klonopin |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Anafranil, buspar, inderal |
|
|
Term
|
Definition
| lowered polysynaptiv reflexes in spinal cord and limbic structures. Potentiates effect of GABA (inhibitory neurotransmitter) |
|
|
Term
| AntiPsychotic Classifications |
|
Definition
| Phenothiazines, Butyrophenones, Dihydroindolones, Thioxanthenes, Dibenzoxazepine, Other (Clozaril, Risperdal, Zyprexa, Seroquel, Geodon, Abilify, Invega) |
|
|
Term
|
Definition
| thorazine, stelazine, prolixin, trilafon, mellaril |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| other typical antipsychotic meds |
|
Definition
|
|
Term
| other atypical antipsychotic meds |
|
Definition
Zyprexa, Seroquel, Geodon, Abilify, Invega, (Risperdal, Clozaril)
S/E - weight gain, HA, drowsiness |
|
|
Term
| antipsychotic med side effects |
|
Definition
| 4 EPR - akathisia (motor restlessness), dystonia, pseudi-parkinsonism, persistent tardive dyskinesia. Others: orthostatic hypotension, blurred vision, photosensitive, agranulocytosis, endocrine changes, decreased seizure threshhold, anticholinergic side effects, arrhythmias |
|
|
Term
|
Definition
| d/t blocking dopamine + seratonin at receptor site |
|
|
Term
| Antidepressant classifications used for antianxiety |
|
Definition
| SSRI, MAOI, TCA, B blocker, SNRI |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| B Blockers for anti anxiety |
|
Definition
|
|
Term
|
Definition
Cogentin, Akineton, Artane, Amantadine (dopaminergic), diphenhydramine
S/E anticholingergic - blurred vision, dry mouth, constipation, sedation, urinary retention, tachycardia |
|
|
Term
| MOA for antiparkinsonism meds |
|
Definition
| Blocks anticholinergic activity in CNS, which is partially responsible for the symptoms of parkinson's disease. Restores natural balance of neurotransmitters in CNS |
|
|
Term
|
Definition
|
|
